A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at ...

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation. Dr ...

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and ...

Please provide your email address to receive an email when new articles are posted on . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) management demands a patient-centered approach ...

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens. What types of adverse effects may patients ...

Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w7g2gd/relapsed_chronic) has announced the addition of the "Relapsed Chronic ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...